Ascierto PA et al. NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma. ASCO 2023;Abstract 9576.
Barrios DM et al. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol 2020;83(5):1239-53. Abstract
Brahmer JR et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018;36(17):1714-68. Abstract
Carter JB et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: An 11-year cohort study. JAMA Dermatol 2013;149(1):35-41. Abstract
Cives M et al. Non-melanoma skin cancers: Biological and clinical features. Int J Mol Sci 2020;21(15):5394. Abstract
Collins L et al. Skin cancer and immunosuppression. Dermatol Clin 2019;37(1):83-94. Abstract
Dummer R et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 2020;182(6):1369-78. Abstract
Dummer R et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016;75(1):113-25.e5. Abstract
Garrett GL et al. Incidence of and risk factors for skin cancer in organ transplant recipients in the United States. JAMA Dermatol 2017;153(3):296-303. Abstract
Grob J-J et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase II trial (KEYNOTE-629). J Clin Oncol 2020;38(25):2916-25. Abstract
Gross ND et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 2022;387(17):1557-68. Abstract
Habashy S et al. Hedgehog pathway inhibitors: Clinical implications and resistance in the treatment of basal cell carcinoma. Cureus 2021;13(3):e13859. Abstract
Hanna GJ et al. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer 2020;123(10):1535-42. Abstract
Haydon AM et al. A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS). ASCO 2022;Abstract TPS9593.
Jarkowski A 3rd et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): The Roswell Park experience and a review of the literature. Am J Clin Oncol 2016;39(6):545-8. Abstract
Karia PS et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32(4):327-34. Abstract
Lacouture ME et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 2016;21(10):1218-29. Abstract
Lam JKS et al. Immunocompromised patients with metastatic cutaneous nodal squamous cell carcinoma of the head and neck: Poor outcome unrelated to the index lesion. Head Neck 2018;40(5):985-92. Abstract
Lear JT et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018;32(3):372-81. Abstract
Lowe MC et al. Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma. ASCO 2021;Abstract TPS9593.
Marin-Acevedo JA et al. Cetuximab for immunotherapy-refractory/ineligible cutaneous squamous cell carcinoma. Cancers (Basel) 2023;15(12):3180. Abstract
Maubec E et al. Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas. J Clin Oncol 2020;38(26):3051-61. Abstract
Maubec E et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29(25):3419-26. Abstract
Menzies AM et al. Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021;27(2):301-9. Abstract
Migden MR et al. An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS). ASCO 2022;Abstract TPS9597.
Migden MR et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21(2):294-305. Abstract
Migden MR et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379(4):341-51. Abstract
Migden MR et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015;16(6):716-28. Abstract
Nikanjam M et al. Advanced basal cell cancer: Concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol 2018;29(11):2192-9. Abstract
Pervan M et al. Investigation of calcium electroporation (CaEP) therapy in malignant cutaneous and subcutaneous tumours: A non-randomized phase II clinical trial of a novel palliative therapy. ESMO 2022;Abstract 1295TiP.
Pickering CR et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 2014;20(24):6582-92. Abstract
Rischin D et al. C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC). ASCO 2022;Abstract TPS9592.
Rischin D et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: Extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 2021;9(8):e002757. Abstract
Schenker M et al. Adjuvant pembrolizumab versus placebo in high-risk locally advanced cutaneous squamous cell carcinoma: The phase 3 KEYNOTE-630 study. AADA 2022;Abstract 34762.
Schnek KM et al. Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers. ASCO 2022;Abstract 9507.
Sekulic A et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017;17(1):332. Abstract
Sekulic A et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366(23):2171-9. Abstract
Stratigos AJ et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):848-57. Abstract
Yarchoan M et al. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 2017;377(25):2500-1. Abstract
Zuur CL et al. Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: An investigator-initiated randomized phase II trial — the MATISSE trial. ASCO 2023;Abstract 9507.